Cardiometabolic Effects of Non-Nutritive Sweeteners (NNS) in Type 1 Diabetes (T1D)
Key facts
- Where
- Milwaukee, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 15 and 24 years old?
Source: NCT07434544, who can take part
Where in United States
- Medical College of WisconsinMilwaukee, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Medical College of Wisconsin
- Trial code
- NCT07434544
- Record updated
- 20 October 2026
- Original description
This project will apply a novel non-nutritive sweetener (NNS) dietary assessment tool with measurement of circulating NNS levels in a pediatric population, allowing correlation of NNS exposure to clinically meaningful cardiometabolic health outcomes.Read full original descriptionShow less
The Cardiometabolic Impact of Non-Nutritive Sweeteners in Young Adults With Type 1 Diabetes
This project will apply a novel non-nutritive sweetener (NNS) dietary assessment tool with measurement of circulating NNS levels in a pediatric population, allowing correlation of NNS exposure to clinically meaningful cardiometabolic health outcomes.
Inclusion: Aged 15-24 years; Clinical diagnosis of type 1 diabetes, requiring insulin therapy, of ≥ 1 to < 10 years duration; Last available HbA1c ≤ 8.5% (obtained by chart review in Children's Wisconsin Diabetes Clinic patients or verbally by individuals not receiving diabetes care at Children's Wisconsin); Current use of an FDA approved automated insulin delivery (AID) system; Willing to consume a 12 ounce Gatorade G Zero Glacier Cherry drink in less than 10 minutes; Willing and able to give informed consent or have parent or legal guardian provide informed consent if the subject is < 18 years of age.
Exclusion: Known cardiovascular disease such as hypertension or atherosclerosis, and/or use of an anti-hypertensive medication; Known renal disease or microalbuminuria, and/or use of angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blockers (ARBs) for microalbuminuria; Raynaud's phenomenon or other vascular disease; Any condition that, in the investigator's opinion, may compromise study participation or may confound the interpretation of the study results; Any disease other than type 1 diabetes that affects glucose, sex steroid, or fat metabolism such as polycystic ovary syndrome or hypercortisolism; Any medication use that may affect glucose, sex steroid, or fat metabolism such as metformin or glucocorticoids; Known hyperlipidemia, defined as LDL ≥ 160 mg/dL, and/or use of lipid-lowering medication, such as statin therapy; Half or full sibling already participating in this study; Known diabetic retinopathy or neuropathy; Obesity and/or body habitus that precludes completion of the flow-mediated brachial ultrasound study (generally, BMI > 40 kg/m2 in adults) - this is at study team's discretion; Pregnancy or lactation.